The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.
Open accessAbstract
Serum tumour necrosis factor alpha (TNF alpha) concentrations were measured by enzyme linked immunoadsorbent assay in 31 normal children and during 65 episodes of clinical remission and 54 episodes of relapse in 92 children with chronic inflammatory bowel disease. An appreciable rise in TNF alpha was found only in children in relapse of ulcerative colitis and colonic Crohn's disease. The group of children with small bowel Crohn's disease in relapse did not show increases of TNF alpha above control concentrations, despite an equivalent rise in disease indices. Height velocity was depressed in children with relapse of large bowel Crohn's disease and ulcerative colitis compared with the equivalent condition in remission. The impairment of growth velocity was significantly greater in relapse of large bowel Crohn's disease and ulcerative colitis than in small bowel Crohn's disease alone, although for the subgroups in stage 1 puberty (prepubertal) the differences were not significant. Inadequate growth in chronic inflammatory bowel disease is currently ascribed to inadequate nutrition and TNF alpha may contribute to this through its cachexia inducing effects. It may, in addition, diminish pituitary growth hormone release. These results suggest that production of TNF alpha may be associated with growth failure in relapse of colonic inflammatory bowel disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection of circulating tumor necrosis factor after endotoxin administration
Michie, H. R., Manogue, K. R., Spriggs, D. R., Revhaug, A., O'Dwyer, S., Dinarello, C. A., Cerami, A., Wolff, S. M., & Wilmore, D. W. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806093182301 · Cited by 1,677
Waage, A., Halstensen, A., & Espevik, T. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91728-4 · Cited by 1,096
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.
Tracey, K. J., Wei, H., Manogue, K. R., Fong, Y., Hesse, D. G., Nguyen, H. T., Kuo, G. C., Beutler, B., Cotran, R. S., & Cerami, A. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.3.1211 · Cited by 730
Tumors secreting human TNF/cachectin induce cachexia in mice
Oliff, A., Defeo-Jones, D., Boyer, M., Martinez, D., Kiefer, D., Vuocolo, G., Wolfe, A., & Socher, S. H. (1987) · Cell · doi:10.1016/0092-8674(87)90028-6 · Cited by 640
PATHOGENESIS OF CROHN'S DISEASE: MULTIFOCAL GASTROINTESTINAL INFARCTION
Wakefield, A. J., Dhillon, A. P., Rowles, P. M., Sawyerr, A. M., Pittilo, R. M., Lewis, A. A. M., & Pounder, R. E. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91078-7 · Cited by 572
A Macrophage Factor Inhibits Adipocyte Gene Expression: An in Vitro Model of Cachexia
Torti, F. M., Dieckmann, B., Beutler, B., Cerami, A., & Ringold, G. M. (1985) · Science · doi:10.1126/science.3839597 · Cited by 518
Tracey, K., Vlassara, H., & Cerami, A. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92394-5 · Cited by 490
MACDONALD, T. T., HUTCHINGS, P., CHOY, M.-Y., MURCH, S., & COOKE, A. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb03334.x · Cited by 478
Self-citationRAISED SERUM LEVELS OF TUMOUR NECROSIS FACTOR IN PARASITIC INFECTIONS
Scuderi, P., Lam, K., Ryan, K., Petersen, E., Sterling, K., Finley, P., Ray, C. G., Slymen, D., & Salmon, S. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92007-6 · Cited by 458
EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCER
Balkwill, F., Burke, F., Talbot, D., Tavernier, J., Osborne, R., Naylor, S., Durbin, H., & Fiers, W. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91850-2 · Cited by 418
Cited by
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60150-0 · Cited by 2,078
Inflammatory bowel disease: Etiology and pathogenesis
Fiocchi, C. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70381-6 · Cited by 2,059
Hanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease
Segain, J.-P., de la Blétière, D. R., Bourreille, A., Leray, V, Gervois, N., Rosales, C., Ferrier, L., Bonnet, C., Blottière, H. M., & Galmiche, J.-P. (2000) · Gut · doi:10.1136/gut.47.3.397 · Cited by 1,321
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D. G., Panaccione, R., Wolf, D., Kent, J. D., Bittle, B., et al. (2007) · Gut · doi:10.1136/gut.2006.106781 · Cited by 1,039
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
Reinisch, W., Sandborn, W. J., Hommes, D. W., D'Haens, G., Hanauer, S., Schreiber, S., Panaccione, R., Fedorak, R. N., Tighe, M. B., Huang, B., et al. (2011) · Gut · doi:10.1136/gut.2010.221127 · Cited by 892
REINECKER, H.-C., STEFFEN, M., WITTHOEFT, T., PFLUEGER, I., SCHREIBER, S., MacDERMOTT, R. P., & RAEDLER, A. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1993.tb05997.x · Cited by 856
Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
Braegger, C. P., Nicholls, S., Murch, S. H., MacDonald, T. T., & Stephens, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)90999-j · Cited by 683
Self-citationDextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice
Dieleman, L. A., Ridwan, B. U., Tennyson, G. S., Beagley, K. W., Bucy, R. P., & Elson, C. O. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90803-6 · Cited by 677
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Ford, A. C., Sandborn, W. J., Khan, K. J., Hanauer, S. B., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.73 · Cited by 604
Lügering, A., Schmidt, M., Lügering, N., Pauels, H.-G., Domschke, W., & Kucharzik, T. (2001) · Gastroenterology · doi:10.1053/gast.2001.28702 · Cited by 588
Schreiber, S., Rutgeerts, P., Fedorak, R. N., Khaliq–Kareemi, M., Kamm, M. A., Boivin, M., Bernstein, C. N., Staun, M., Thomsen, O. Ø., & Innes, A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.064 · Cited by 580
Breese, E. J., Michie, C. A., Nicholls, S. W., Murch, S. H., Williams, C. B., Domizio, P., Walker-Smith, J. A., & Macdonald, T. T. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90398-0 · Cited by 566
Self-citationMurch, S. H., Braegger, C. P., Walker-Smith, J. A., & MacDonald, T. T. (1993) · Gut · doi:10.1136/gut.34.12.1705 · Cited by 520
Self-citationSandborn, W. J., & Hanauer, S. B. (1999) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199905000-00008 · Cited by 454
Reuter, B. K., Asfaha, S., Buret, A., Sharkey, K. A., & Wallace, J. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119013 · Cited by 423
Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers
Aggarwal, B. B., Gupta, S. C., & Sung, B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12131 · Cited by 395
The Role of Inflammation in Venous Thromboembolism
Branchford, B. R., & Carpenter, S. L. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00142 · Cited by 384
Probert, C. S. J., Hearing, S. D., Schreiber, S., Kühbacher, T., Ghosh, S., Arnott, I. D. R., & Forbes, A. (2003) · Gut · doi:10.1136/gut.52.7.998 · Cited by 355
Ford, A. C., & Peyrin-Biroulet, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.138 · Cited by 343
Matrix metalloproteinase levels are elevated in inflammatory bowel disease
Baugh, M. D., Perry, M. J., Hollander, A. P., Davies, D. R., Cross, S. S., Lobo, A. J., Taylor, C. J., & Evans, G. S. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70339-2 · Cited by 328
Isaacs, K. L., Sartor, R. B., & Haskill, S. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91182-4 · Cited by 314
Tumour-necrosis-factor antibody treatment in Crohn's disease
Derkx, B., Taminiau, J., Radema, S., Stronkhorst, A., Wortel, C., Tytgat, G., & van Deventer, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)91375-v · Cited by 308
The Key Role of Macrophages in the Immunopathogenesis of Inflammatory Bowel Disease
Mahida, Y. R. (2000) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200002000-00004 · Cited by 293
Taming TNF: strategies to restrain this proinflammatory cytokine
Eigler, A., Sinha, B., Hartmann, G., & Endres, S. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01118-3 · Cited by 284
Foell, D., Kucharzik, T., Kraft, M., Vogl, T., Sorg, C., Domschke, W., & Roth, J. (2003) · Gut · doi:10.1136/gut.52.6.847 · Cited by 279
Anti-TNF Therapy in Crohn’s Disease
Adegbola, S. O., Sahnan, K., Warusavitarne, J., Hart, A., & Tozer, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082244 · Cited by 274
Helicobacter pylori infection in childhood: risk factors and effect on growth
Patel, P., Mendall, M. A., Khulusi, S., Northfield, T. C., & Strachan, D. P. (1994) · BMJ · doi:10.1136/bmj.309.6962.1119 · Cited by 260
Sandborn, W. J., Feagan, B. G., Hanauer, S. B., Present, D. H., Sutherland, L. R., Kamm, M. A., Wolf, D. C., Baker, J. P., Hawkey, C., Archambault, A., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.24042 · Cited by 257
Immune dysfunction in inflammatory bowel disease
Neuman, M. G. (2007) · Translational Research · doi:10.1016/j.trsl.2006.11.009 · Cited by 255
Cope, A. P., Londei, M., Chu, N. R., Cohen, S. B., Elliott, M. J., Brennan, F. M., Maini, R. N., & Feldmann, M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117394 · Cited by 243
Straub, R. H., Herfarth, H., Falk, W., Andus, T., & Schölmerich, J. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00047-4 · Cited by 115
Subcutaneous Bioavailability of Golimumab at 3 Different Injection Sites in Healthy Subjects
Xu, Z., Wang, Q., Zhuang, Y., Frederick, B., Yan, H., Bouman‐Thio, E., Marini, J. C., Keen, M., Snead, D., Davis, H. M., et al. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009340782 · Cited by 97
Belmiro, C. L. R., Castelo-Branco, M. T. L., Melim, L. M. C., Schanaider, A., Elia, C., Madi, K., Pavão, M. S. G., & de Souza, H. S. P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807211200 · Cited by 57
Metadata
- Authors
- Murch, S. H., Lamkin, V. A., Savage, M. O., Walker-Smith, J. A., & MacDonald, T. T.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 1991-08
- Volume
- 32
- Issue
- 8
- Pages
- 913-917
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2040401921
- Cited by
- 482
- References
- 39
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.